“Primary myelofibrosis (PMF) can be treated with allogenic stem cell transplant (which can cure the disease or prolong survival) or with drug therapy, splenectomy, and radiation. Determining the appropriate time for a transplant is an important objective in tailoring treatment to the individual patient, and currently, the mutation- and karyotype-enhanced prognostic scoring system (MIPSS70 +… Read More »NEW PREDICTIVE MODEL DEVELOPED FOR LEUKEMIC TRANSFORMATION IN PRIMARY MYELOFIBROSIS
he MPN Research Foundation is proud to announce the opening of our 2019 call for proposals for the MPN Challenge™ Grant Program. We are excited to once again partner with the Leukemia & Lymphoma Society on this endeavor, which seeks to fund the most innovative MPN research. The application deadline is April 1, 2019. All… Read More »MPNRF RELEASES 2019 REQUEST FOR PROPOSALS
“Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF), data are limited on how molecular markers predict transplantation outcomes. We retrospectively evaluated transplantation outcomes of 110 consecutive MF patients who underwent allo-HCT with a fludarabine/melphalan (Flu/Mel) conditioning regimen at our center and assessed the impact of molecular markers on outcomes based… Read More »MIPSS70+ V2.0 PREDICTS LONG-TERM SURVIVAL IN MYELOFIBROSIS AFTER ALLOGENEIC HCT WITH THE FLU/MEL CONDITIONING REGIMEN
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs Constellation CEO Jigar Raythatha will present at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 4PM PST/7PM EST The presentation will include updated results from the first four patients in the MANIFEST Phase 2 clinical… Read More »CONSTELLATION PHARMACEUTICALS PROVIDES UPDATE ON MANIFEST CLINICAL TRIAL OF CPI-0610 IN MYELOFIBROSIS
Breaking news for ropeginterferon: CHMP (The Committee for Medicinal Products for Human Use; European Medicines Agency’s committee responsible for elaborating the agency’s opinions on all issues regarding medicinal products for human use) has given a positive opinion on the drug and recommended granting market authorization. If approved, this will be the first time an interferon… Read More »CHMP RECOMMENDED GRANTING MARKETING AUTHORIZATION FOR ROPEGINTERFERON
The MPN Research Foundation has an exciting announcement to make! This fall, in collaboration with MPN Advocacy & Education Int’l, The Leukemia & Lymphoma Society and UT Health San Antonio MD Anderson Cancer Center, MPNRF will be holding an externally led patient-focused drug development (PFDD) meeting with the U.S. Food and Drug Administration (FDA). This meeting is a long-awaited opportunity for the… Read More »EXCITING ANNOUNCEMENT FROM MPNRF!
In a recent study published today in The New England Journal of Medicine, doctors were able to define eight genomic subgroups of MPN patients, using a study of 2,035 people, and then integrated 63 clinical and genomic variables to create a prognostic model capable of generating personally tailored predictions of clinical outcomes in patients with MPNs.… Read More »CLASSIFICATION AND PROGNOSTIC MODELS DEVELOPED FOR MPN PATIENT OUTCOMES
Today Janssen announced that they would no longer be partnering with Geron on the development of Imetelstat, which was being tested for use in Myelofibrosis. According to the statement by Janssen, the pharmaceutical company “will work with Geron to transition the imetelstat program back to the company. Patients currently enrolled in the ongoing imetelstat clinical trials will… Read More »JANSSEN ELECTS NOT TO CONTINUE AGREEMENT WITH GERON FOR IMETELSTAT
The FDA announced that they have awarded 12 new clinical trial research grants toward advancing the development of treatments of rare diseases. We are pleased the FDA is investing in rare diseases. While they are not directly funding PV, ET or MF research two of the projects are related. Dr. Yang Liu with Oncolmmune, Inc.… Read More »FDA AWARDS $18 MILLION IN GRANTS FOR ADVANCING TREATMENT OF RARE DISEASES
The MPN Research Foundation in Prague. Once a year, for the last three years, a growing number of MPN patient advocacy groups from across the globe, have been meeting to learn more about new treatments being developed for patients and how best to engage the patient community. The MPN Advocates Network, who organizes the annual… Read More »MPN RESEARCH FOUNDATION ATTENDS 3RD ANNUAL MPN HORIZONS CONFERENCE
